0

Close
 
Upcoming Allied Market Research
2023
Desynchronosis Treatment Market

Desynchronosis Treatment Market

by Product (Prescription Drugs, Over-the-counter Drugs) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13343
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Desynchronosis Treatment Market

Request Now !

Since inception of commercial and defense-related air travel, there has been constant increase in the number of people travelling on international tours. In addition, globalization has fueled the idea of global village with higher rate of people travelling to different countries for travel, work purpose, and formal trade relations. A common complaint associated with frequent air travel is “jet lag.” It results from body’s inability to readjust to rapid changes in time and external macroenvironment. This results in increased fatigue, decreased energy levels, and distorted body metabolism. Over the years, various advanced therapeutics have been deployed, as portable treatment options for jet lag, including intermittent sleeping patterns and use of melatonin.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global desynchronosis treatment market.

Top Impacting Factors

  • Exponential in the number of air travel each year disrupts sleep patterns, body metabolism, and gastro intestinal tract resulting in alterations of body clock also known as circadian rhythms. This, in turn, has paved way for easy and quick treatment therapeutics to treat jet lags.
  • Rise in globalization, influx of global trade, supply chain widening, globalized planned migrations and the growing idea of one globalized village resulting in frequent air travels across continents and regions drive the demand for desynchronosis treatment.
  • Advantages associated with deploying easy-to-use portable wearable technologies to monitor cardiovascular patterns especially in regions with high disposable income and better skilled personnel support for the growth of the desynchronosis treatment market.
  • However, cases of drug addictions attached with the use of these advanced therapeutics to treat jet lags. Among these, addictions attached to melatonin are the most frequent ones that might hamper market growth.
  • Additionally, less purchasing power parity and low awareness regarding new age portable wearable technologies in underdeveloped nations might hamper market penetration into these areas.

Key Market Trends

  • North America is anticipated to gain significant market traction, owing increased use of melatonin as a viable solution against desynchronosis. In addition, the region holds highest number of regional and global manufacturers, thus providing them with an array of frequent product trials, etc.
  • Researchers are working on the possibility of curing jet lags through barefoot grass walking technique. Under this, the patients are to be advised to walk over clean, natural grass barefoot for a stipulated time. The technique under initial trails has shown great psychological results by balancing the sleep pattern and body metabolism trade off.
  • Neuroon is a revolutionary and utterly successful device that was established as a possible countermeasure against jet lags. The device incorporates advanced brain wave and pulse measurement mechanisms to improve sleep patterns. It further uses biometric sensors to study person’s sleep architecture and offer sleep optimization routine.
  • Recently, light therapy has come under intense consideration as a viable jet lag treatment alternative. The mechanism is employed to at night to speed up brain’s adjustments toward time changes with the help of a technique known as “biological hacking.”
  • Use of hypnotics has been proposed to balance the tradeoff between sleep cycle and time changes.
  • Triazolam, an advanced therapeutic drug, has been see to block jet lag effects in early clinical trials thus realigning the circadian cycles. However, the efficacy of the drug at a larger level is still highly questionable.
  • NASA studies have proposed the idea of regular intermittent napping as a countermeasure to desynchronosis. The technique has shown results with NASA’s Hubble aircraft with aircrew taking short naps in between to balance out their circadian cycles, and thus is being further proposed for commercial air travel as well.

Key Benefits of the Report

  • This study presents the analytical depiction of the desynchronosis treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the desynchronosis treatment market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in Desynchronosis Treatment Report

  • Which are the leading players active in the desynchronosis treatment market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the desynchronosis treatment market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is desynchronosis treatment?
  • What is the desynchronosis treatment market prediction in the future?
  • What are the current trends and predicted trends?

 Desynchronosis Treatment Market Report Highlights

Aspects Details
By Product
  • Prescription Drugs
  • Over-the-counter Drugs
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players NOW Foods, ALEXZA, Clinigen Group plc, Jamieson Laboratories Ltd., Eisai Co., Ltd., Vanda Pharmaceuticals Inc., Purdue Pharma L.P, Nature's Bounty, Jazz Pharmaceuticals, Inc., Pfizer Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: DESYNCHRONOSIS TREATMENT MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Prescription Drugs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Over-the-counter Drugs

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: DESYNCHRONOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Distribution Channel

    • 5.2. Hospital Pharmacies

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Retail Pharmacies

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Online Pharmacies

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: DESYNCHRONOSIS TREATMENT MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Distribution Channel

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Desynchronosis Treatment Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Distribution Channel

      • 6.2.6. Canada Desynchronosis Treatment Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Distribution Channel

      • 6.2.7. Mexico Desynchronosis Treatment Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Distribution Channel

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Distribution Channel

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Desynchronosis Treatment Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Distribution Channel

      • 6.3.6. Germany Desynchronosis Treatment Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Distribution Channel

      • 6.3.7. Italy Desynchronosis Treatment Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Distribution Channel

      • 6.3.8. Spain Desynchronosis Treatment Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Distribution Channel

      • 6.3.9. UK Desynchronosis Treatment Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Distribution Channel

      • 6.3.10. Russia Desynchronosis Treatment Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Distribution Channel

      • 6.3.11. Rest Of Europe Desynchronosis Treatment Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Distribution Channel

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Distribution Channel

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Desynchronosis Treatment Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Distribution Channel

      • 6.4.6. Japan Desynchronosis Treatment Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Distribution Channel

      • 6.4.7. India Desynchronosis Treatment Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Distribution Channel

      • 6.4.8. South Korea Desynchronosis Treatment Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Distribution Channel

      • 6.4.9. Australia Desynchronosis Treatment Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Distribution Channel

      • 6.4.10. Thailand Desynchronosis Treatment Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Distribution Channel

      • 6.4.11. Malaysia Desynchronosis Treatment Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Distribution Channel

      • 6.4.12. Indonesia Desynchronosis Treatment Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Distribution Channel

      • 6.4.13. Rest of Asia Pacific Desynchronosis Treatment Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Distribution Channel

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Distribution Channel

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Desynchronosis Treatment Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Distribution Channel

      • 6.5.6. South Africa Desynchronosis Treatment Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Distribution Channel

      • 6.5.7. Saudi Arabia Desynchronosis Treatment Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Distribution Channel

      • 6.5.8. UAE Desynchronosis Treatment Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Distribution Channel

      • 6.5.9. Argentina Desynchronosis Treatment Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Distribution Channel

      • 6.5.10. Rest of LAMEA Desynchronosis Treatment Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Distribution Channel

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Clinigen Group Plc

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Vanda Pharmaceuticals Inc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Pfizer Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Jamieson Laboratories Ltd.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. NOW Foods

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Nature's Bounty

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. ALEXZA

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Jazz Pharmaceuticals, Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Eisai Co., Ltd.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Purdue Pharma L.P

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DESYNCHRONOSIS TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL DESYNCHRONOSIS TREATMENT MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL DESYNCHRONOSIS TREATMENT MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL DESYNCHRONOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL DESYNCHRONOSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL DESYNCHRONOSIS TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL DESYNCHRONOSIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL DESYNCHRONOSIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL DESYNCHRONOSIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA DESYNCHRONOSIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 13. U.S. DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 14. U.S. DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 15. CANADA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 16. CANADA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE DESYNCHRONOSIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. ITALY DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. ITALY DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. UK DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. UK DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC DESYNCHRONOSIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. CHINA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. CHINA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. INDIA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. INDIA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA DESYNCHRONOSIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. UAE DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. UAE DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA DESYNCHRONOSIS TREATMENT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA DESYNCHRONOSIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. CLINIGEN GROUP PLC: KEY EXECUTIVES
  • TABLE 73. CLINIGEN GROUP PLC: COMPANY SNAPSHOT
  • TABLE 74. CLINIGEN GROUP PLC: OPERATING SEGMENTS
  • TABLE 75. CLINIGEN GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 76. CLINIGEN GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. VANDA PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 78. VANDA PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 79. VANDA PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 80. VANDA PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 81. VANDA PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. PFIZER INC.: KEY EXECUTIVES
  • TABLE 83. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 84. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 85. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 86. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. JAMIESON LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 88. JAMIESON LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 89. JAMIESON LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 90. JAMIESON LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 91. JAMIESON LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. NOW FOODS: KEY EXECUTIVES
  • TABLE 93. NOW FOODS: COMPANY SNAPSHOT
  • TABLE 94. NOW FOODS: OPERATING SEGMENTS
  • TABLE 95. NOW FOODS: PRODUCT PORTFOLIO
  • TABLE 96. NOW FOODS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. NATURE'S BOUNTY: KEY EXECUTIVES
  • TABLE 98. NATURE'S BOUNTY: COMPANY SNAPSHOT
  • TABLE 99. NATURE'S BOUNTY: OPERATING SEGMENTS
  • TABLE 100. NATURE'S BOUNTY: PRODUCT PORTFOLIO
  • TABLE 101. NATURE'S BOUNTY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. ALEXZA: KEY EXECUTIVES
  • TABLE 103. ALEXZA: COMPANY SNAPSHOT
  • TABLE 104. ALEXZA: OPERATING SEGMENTS
  • TABLE 105. ALEXZA: PRODUCT PORTFOLIO
  • TABLE 106. ALEXZA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. JAZZ PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 108. JAZZ PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 109. JAZZ PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 110. JAZZ PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 111. JAZZ PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. EISAI CO., LTD.: KEY EXECUTIVES
  • TABLE 113. EISAI CO., LTD.: COMPANY SNAPSHOT
  • TABLE 114. EISAI CO., LTD.: OPERATING SEGMENTS
  • TABLE 115. EISAI CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 116. EISAI CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. PURDUE PHARMA L.P: KEY EXECUTIVES
  • TABLE 118. PURDUE PHARMA L.P: COMPANY SNAPSHOT
  • TABLE 119. PURDUE PHARMA L.P: OPERATING SEGMENTS
  • TABLE 120. PURDUE PHARMA L.P: PRODUCT PORTFOLIO
  • TABLE 121. PURDUE PHARMA L.P: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DESYNCHRONOSIS TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DESYNCHRONOSIS TREATMENT MARKET
  • FIGURE 3. SEGMENTATION DESYNCHRONOSIS TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DESYNCHRONOSIS TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDESYNCHRONOSIS TREATMENT MARKET
  • FIGURE 11. DESYNCHRONOSIS TREATMENT MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. DESYNCHRONOSIS TREATMENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. DESYNCHRONOSIS TREATMENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. DESYNCHRONOSIS TREATMENT MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 15. DESYNCHRONOSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. DESYNCHRONOSIS TREATMENT MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. DESYNCHRONOSIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. DESYNCHRONOSIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: DESYNCHRONOSIS TREATMENT MARKET
  • FIGURE 25. Top player positioning, 2022
  • FIGURE 26. CLINIGEN GROUP PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. CLINIGEN GROUP PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. CLINIGEN GROUP PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. VANDA PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. VANDA PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. VANDA PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. JAMIESON LABORATORIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. JAMIESON LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. JAMIESON LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. NOW FOODS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. NOW FOODS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. NOW FOODS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. NATURE'S BOUNTY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. NATURE'S BOUNTY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. NATURE'S BOUNTY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. ALEXZA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. ALEXZA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. ALEXZA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. JAZZ PHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. JAZZ PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. JAZZ PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. EISAI CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. EISAI CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. EISAI CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. PURDUE PHARMA L.P: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. PURDUE PHARMA L.P: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. PURDUE PHARMA L.P: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Desynchronosis Treatment Market

Start reading.
This Report and over 67,112+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers